Search
for
Sort by
Research 571–600 of 1000+
- The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
- Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
- What do we know about phytotherapy of benign prostatic hyperplasia?
- Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
- Herbs for Benign Prostatic Hyperplasia
- Association of Benign Prostatic Hyperplasia with Male Pattern Baldness
- Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy
- Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review
- Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
- Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia
- Endocrinology of the Aging Prostate: Current Concepts
- 5α‐Reductase inhibitors and prostatic disease
- Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia
- Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction
- Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia
- α-spinasterol from Melandrium firmum attenuates benign prostatic hyperplasia in a rat model
- Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia
- Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study
- The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model
- Docking and Molecular Dynamics Identify Leads against 5 Alpha Reductase 2 for Benign Prostate Hyperplasia Treatment
- Development of prostate cancer in a patient with primary hypogonadism: intratumoural steroidogenesis in prostate cancer tissues
- Therapeutic Considerations Related to Finasteride Administration in Male Androgenic Alopecia and Benign Prostatic Hyperplasia
- A herbal formula, comprising Panax ginseng and bee-pollen, inhibits development of testosterone-induced benign prostatic hyperplasia in male Wistar rats
- Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
- An observational study of the association between androgenetic alopecia and size of the prostate
- Effect of Citrullus colocynthis Schard on Testosterone-Induced Benign Prostatic Hyperplasia
- Contrast-Enhanced Ultrasound (CEUS) Evaluation of Canine Prostatic Hyperplasia before and after Osaterone Acetate Therapy: Preliminary Results
- Presence of Codes for Indication for Use in Clinical Practice Research Datalink Aurum: An Assessment of Benign Prostatic Hyperplasia Treatments
- Patterns of Care for Newly Diagnosed Benign Prostatic Hyperplasia in the United States